Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601378 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT02601378: Clinical Trial Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT02601378 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 107 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02601378, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Primary Outcome
cycle = 28 days
Interventions
- DRUG LXS196
- DRUG LXS196 and HDM201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2022-01-07 |
| Phase | Phase 1 |
Why NCT02601378 stopped before completion
NCT02601378 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 2 interventions - of which LXS196 is the first listed.
NCT02601378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02601378 about?
NCT02601378 is a clinical study titled "A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.". This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
What is the current status of trial NCT02601378?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2016-02-01. Estimated completion is 2022-01-07.
What interventions are being tested in trial NCT02601378?
The interventions under investigation include: LXS196 (DRUG), LXS196 and HDM201 (DRUG).
Who is sponsoring clinical trial NCT02601378?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02601378's enrollment target sits among peer trials
107 531st of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI